Adventrx Pharmaceuticals has initiated a Phase III pivotal clinical trial for its chemotherapy-enhancing drug candidate CoFactor in metastatic colorectal cancer.

The trial is a multicenter, 1,200-patient study in the first-line treatment of patients with metastatic colorectal cancer. Patients will be equally randomized to two arms containing either CoFactor or leucovorin, each in combination with 5-FU and bevacizumab, which is marketed by Roche and Genentech as Avastin.